TABLE 1.
Factors associated with 30-day mortality among MRSA-B patients treated with VAN
| Factora | Value for patients with: |
P value | |
|---|---|---|---|
| No mortality (n = 42) | Mortality (n = 11) | ||
| Age (yr), means ± SD | 58.5 ± 15.9 | 70.6 ± 16.6 | 0.031 |
| ≥65 yr, n (%) | 17 (40.5) | 7 (63.6) | 0.170 |
| ≥85 yr, n (%) | 1 (2.4) | 3 (27.3) | 0.025 |
| Female gender, n (%) | 15 (35.7) | 3 (27.3) | 0.730 |
| Previous VAN exposure within 30 days, n (%) | 4 (9.5) | 5 (45.5) | 0.031 |
| Hospital-acquired MRSA-B, n (%) | 12 (28.6) | 6 (54.5) | 0.105 |
| ICU, n (%) | 10 (23.8) | 6 (54.5) | 0.048 |
| Sepsis, n (%) | 27 (64.3) | 9 (81.8) | 0.267 |
| Septic shock, n (%) | 6 (14.3) | 2 (18.2) | 0.665 |
| Immunosuppression, n (%) | 10 (23.8) | 4 (36.4) | 0.453 |
| MRSA-B focus | |||
| High risk, n (%) | 10 (23.8) | 8 (72.7) | 0.002 |
| Medium risk, n (%) | 26 (61.9) | 2 (18.2) | 0.016 |
| Low risk, n (%) | 6 (14.3) | 1 (9.1) | 1.000 |
| MRSA bacteriuria, n (%) | 4 (9.5) | 1 (9.1) | 1.000 |
| Diabetes mellitus, n (%) | 15 (35.7) | 4 (36.4) | 0.968 |
| Alcoholism, n (%) | 4 (9.5) | 1 (9.1) | 1.000 |
| Cirrhosis, n (%) | 3 (7.1) | 1 (9.1) | 1.000 |
| Congestive heart failure, n (%) | 3 (7.1) | 2 (18.2) | 0.275 |
| Malignancy, n (%) | 8 (19.0) | 7 (63.6) | 0.003 |
| HIV positive, n (%) | 1 (2.4) | 0 (0.0) | 1.000 |
| Chronic obstructive pulmonary disease, n (%) | 5 (11.9) | 2 (18.2) | 0.626 |
| Charlson comorbidity index, median (IQR) | 6 (3–7) | 7 (6–9) | 0.017 |
| PBS, median (IQR) | 1 (0–3) | 4 (1–6) | 0.028 |
| PBS ≥ 4, n (%) | 7 (16.7) | 6 (54.5) | 0.009 |
| APACHE II score, median (IQR) | 11 (7–14) | 17 (14–25) | 0.002 |
a
IQR, interquartile range.